• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

The MiG-TOFU Study: Gestational Diabetes, Metformin and Metabolic Outcomes in Offspring 7 Years Later

image_pdfFavoriteLoadingFavorite

long term

BACKGROUND AND PURPOSE: 

  • Metformin in Gestational diabetes (MiG) trial 
    • RCT of women with GDM, randomized to either metformin (plus supplemental insulin if required) or insulin 
    • Similar outcomes although metformin group had increased rate of preterm birth (12/1% vs 7.6%, p=0.04) and neonates with lower rates of severe hypoglycemia (3.3% vs 8.1%, p=0.009) 
    • Long-term offspring follow-up (TOFU) data are lacking and studies are ongoing  
  • Outcomes at 2 years of age in offspring of women with GDM treated with metformin showed similar total body fat percent, but greater subscapular and biceps skinfolds, as well larger upper arm circumferences  
  • Rowan et al. (BMJ Open Diabetes Research & Care, 2018) present the 7 year follow up data from the MiG trial

METHODS: 

  • Longitudinal follow-up of women recruited to MiG-TOFU study 
  • Women were randomized into groups that received 
    • Metformin  
    • Insulin 
    • Matching control 
  • Children were assessed in Adelaide (7 year follow up) and then Auckland (9 year follow up) using multiple tools 
    • Anthropometry 
    • Bioimpedance analysis (BIA) 
    • Dual-energy X-ray absorptiometry (DXA) 
    • Magnetic resonance imaging (MRI) 
    • Fasting bloods 

RESULTS: 

  • Total participants: 208 
    • 109 Adelaide (7 year) and 99 Auckland (9 year)  
  • There were no differences in offspring measures at 7 years 
  • At 9 years in Auckland, metformin offspring were 
    • Larger by measures of weight, arm and waist circumferences, waist:height (p<0.05) 
    • BMI, triceps skinfold (p=0.05) 
    • DXA fat mass and lean mass (p=0.07) 
    • MRI abdominal fat volume (p=0.051) 
  • All other measures were similar 

CONCLUSION:  

  • Metformin or insulin for GDM was associated with similar offspring total and abdominal body fat percent and metabolic measures at 7-9 years 
  • However, metformin-exposed children were larger at 9 years 
  • Authors state that overall, data related to long-term metformin use is reassuring but further research is needed to understand the findings at 9 years 

Learn More – Primary Sources: 

Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age.

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ACOG and SMFM Both Release Guidance on Gestational Diabetes – Insulin vs Metformin for First-Line Therapy?
Metformin in Pregnancy
Are Metformin or Statins Associated with Increased Risk for Ovarian Cancer in Women with Type 2 Diabetes?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site